Connect with us

3 Biotech Penny Stocks That Are Popular on Reddit Right Now

Looking for biotech penny stocks on Reddit? Check these 3 out for your watchlist
The post 3 Biotech Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Published

on

Reddit Biotech Penny Stocks Remain in Focus in June 2021

Finding penny stocks on Reddit has become a major strategy for all types of investors. While Reddit hasn’t always been the place to find and make a penny stocks watchlist, it is more popular than ever. While there are thousands of penny stocks to choose from, only a handful are mentioned across various sub-Reddits. 

Finding the best ones to buy or add to your watchlist however, can be difficult. The best way to start if you’re thinking about investing in penny stocks, is by doing as much research as you can. This usually begins with a large list of companies of interest. Then, this list can be dwindled down as you discover more and more about each specific penny stock. 

[Read More] 7 Penny Stocks to Watch With Crypto News Sparking a Market Dip

With biotech, it’s important to consider a few things beyond the usual penny stock research. This includes what drugs or tech products are in its pipeline? How far are they along in the approval stages? And, what is the potential market size for that product? These questions will help to determine whether a company has either short or long term value, or both. 

So, with plenty of biotech penny stocks on Reddit, it all comes down to knowing where to look and cementing a strategy. But with this in mind, let’s take a look at three that are popular on Reddit right now. 

3 Reddit Biotech Penny Stocks to Watch 

  1. Second Sight Medical Products Inc. (NASDAQ: EYES
  2. Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP
  3. Tyme Technologies Inc. (NASDAQ: TYME

1. Second Sight Medical Products Inc. (NASDAQ: EYES)

Biotech penny stocks like Second Sight Medical Products Inc. have been in focus recently as the industry continues to grow. This is a company that develops, manufactures, and markets implantable visual prosthetics for delivering artificial vision to the blind.

Its technologies treat sight-impaired people with products such as the Orion Visual Cortical Prosthesis System. This product gives vision capabilities to those suffering from blindness caused by glaucoma, diabetes, optic nerve injury, or something else.

EYES recently announced year three of NIH funding for its early feasibility clinical trial of a visual cortical prosthesis. The NIH released $1.4 million of the $6.4 million planned five-year grant. Because of this, it looks like Second Sight should be well funded into the foreseeable future.

EYES has been increasing in value ever since it recorded positive progress in this trial a few weeks ago. It is always a major positive to see a biotech company that not only is increasing in value, but also making progress with its trials. 

The company reported that five out of the five patients in the study were able to locate a white square on a computer screen “significantly better” with its system. While other companies are working on similar treatments, this is a major breakthrough for those with vision impairments.

In 2021 this biotech penny stock went from about $2 a share to now being over $5.50 per share on average as of May 28th. On May 28th alone, this penny stock shot up by more than 8% during trading.

While it technically is no longer a penny stock, it only recently surpassed the $5 threshold. And given that we’ve covered EYES stock so many times, breaching penny stock territory is always good news. 

Considering all of this, it looks like Second Sight is in both a financially advantageous position as well as moving forward with its planned trials. Considering this, will you be adding EYES to your list of penny stocks to watch?

2. Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP)

Another biotech penny stock that has been trending upwards in the market is Corbus Pharmaceuticals Holdings Inc. Corbus is a clinical stage pharmaceutical company that focuses on developing and commercializing therapeutics for a range of ailments. These treatments are usually for rare, chronic, and serious inflammatory and fibrotic diseases. 

One of its leading products is lenabasum, which is in Phase III clinical trials to treat systemic sclerosis and dermatomyositis. Having a compound in such a late stage of trials is always exciting for investors. It shows that the company could be close to commercialization in the near future. Additionally, it is also developing a cannabinoid receptor type 1 inverse agonist program to treat metabolic disorders like obesity. 

Using cannabinoids as a compound in pharmaceuticals is not new. However, the research is still very limited. Because of its massive potential, this could be a big deal for Corbus moving forward. It also adds it into the marijuana penny stocks list. 

[Read More] 3 Penny Stocks on Reddit Making Big Waves Right Now

On May 25th, the company announced that it will publicize two abstracts at the European League Against Rheumatism 2021 Virtual Congress taking place on June 2-5. These abstracts will talk about the Phase 3 trial of Lenabasum, mentioned above. It will include the progress in myositis and scleroderma research.

The company will also be holding an adjourned meeting for shareholders on June 17th, which potential investors should keep in mind. With all of these upcoming events and its current trials, is Corbus Pharmaceuticals worth adding to your penny stocks watchlist?

Penny_Stocks_to_Watch_Corbus_Pharmaceuticals_Holdings_Inc_CRBP_Stock

3. Tyme Technologies Inc. (NASDAQ: TYME)

Tyme Technologies Inc. is a biotech penny stock that we’ve discussed numerous times in the past few months. This is due to the large degree of progress that TYME stock is seeing right now. If you don’t know about Tyme, let’s get you caught up.

Tyme Technologies is a biotech penny stock that develops cancer metabolism-based therapies in the United States. Because cancer is such a prevalent illness in the U.S. and globally, biotech companies are scrambling to find treatments or cures.

This has been the case for decades. However, the focus on biotech as a result of the pandemic, means things are moving faster than ever before. Because of this, TYME stock remains a focus of many investors right now.

One of its lead products is the SM-88 CMBT that is in Phase II/III clinical trial to treat 15 types of cancer. This includes lung, prostate, breast, and pancreatic cancer among others. It also has TYME-18 which is a CMBT compound in preclinical stages to treat solid tumors.

Both of these could be promising, but they are still relatively in the early stages of approval. However, the fact that these compounds have such broad applications, is always a good sign. Usually a compound will be approved for one or two specific uses. However, given that SM-88 can potentially  treat more than 15 types of cancer, the opportunities here are large.

On May 10th, the company announced that its abstract was selected for publication at the 2021 American Society of Clinical Oncology Annual Meeting on June 4-8. At the meeting, it will discuss Phase II Study of SM-88 in Ewing’s and Other Sarcomas. The company will then host a conference call and live video webcast on Thursday, June 10th. This is when it will report its fiscal year 2021 financial results and provide a business update. 

Financial results are always extremely important with both biotech penny stocks and all penny stocks for that matter. However, given the sheer amount of news that biotech companies put out, speculation remains high regarding any announcement. With all of these upcoming events and TYME stock increase on May 28th by over 4%, will it make it on to your watchlist?

Penny_Stocks_to_Watch_Tyme_Technologies_Inc_TYME_Stock_Chart

Are Reddit Biotech Penny Stocks Worth It?

Finding biotech penny stocks on Reddit can be a great way to start making a watchlist. However, if we combine the speculation of penny stocks, penny stocks on Reddit, and the biotech industry overall; we see that these can be some of the most volatile securities out there. 

[Read More] Investing in Penny Stocks in June 2021? 3 Things Investors Should Know

But, if you have a proper trading education and a commitment to a strategy, investing in biotech penny stocks can be worth it. With all of this in mind, what do you think? Are these companies worth investing in?

The post 3 Biotech Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

International

Chronic stress and inflammation linked to societal and environmental impacts in new study

From anxiety about the state of the world to ongoing waves of Covid-19, the stresses we face can seem relentless and even overwhelming. Worse, these stressors…

Published

on

From anxiety about the state of the world to ongoing waves of Covid-19, the stresses we face can seem relentless and even overwhelming. Worse, these stressors can cause chronic inflammation in our bodies. Chronic inflammation is linked to serious conditions such as cardiovascular disease and cancer – and may also affect our thinking and behavior.   

Credit: Image: Vodovotz et al/Frontiers

From anxiety about the state of the world to ongoing waves of Covid-19, the stresses we face can seem relentless and even overwhelming. Worse, these stressors can cause chronic inflammation in our bodies. Chronic inflammation is linked to serious conditions such as cardiovascular disease and cancer – and may also affect our thinking and behavior.   

A new hypothesis published in Frontiers in Science suggests the negative impacts may extend far further.   

“We propose that stress, inflammation, and consequently impaired cognition in individuals can scale up to communities and populations,” explained lead author Prof Yoram Vodovotz of the University of Pittsburgh, USA.

“This could affect the decision-making and behavior of entire societies, impair our cognitive ability to address complex issues like climate change, social unrest, and infectious disease – and ultimately lead to a self-sustaining cycle of societal dysfunction and environmental degradation,” he added.

Bodily inflammation ‘mapped’ in the brain  

One central premise to the hypothesis is an association between chronic inflammation and cognitive dysfunction.  

“The cause of this well-known phenomenon is not currently known,” said Vodovotz. “We propose a mechanism, which we call the ‘central inflammation map’.”    

The authors’ novel idea is that the brain creates its own copy of bodily inflammation. Normally, this inflammation map allows the brain to manage the inflammatory response and promote healing.   

When inflammation is high or chronic, however, the response goes awry and can damage healthy tissues and organs. The authors suggest the inflammation map could similarly harm the brain and impair cognition, emotion, and behavior.   

Accelerated spread of stress and inflammation online   

A second premise is the spread of chronic inflammation from individuals to populations.  

“While inflammation is not contagious per se, it could still spread via the transmission of stress among people,” explained Vodovotz.   

The authors further suggest that stress is being transmitted faster than ever before, through social media and other digital communications.  

“People are constantly bombarded with high levels of distressing information, be it the news, negative online comments, or a feeling of inadequacy when viewing social media feeds,” said Vodovotz. “We hypothesize that this new dimension of human experience, from which it is difficult to escape, is driving stress, chronic inflammation, and cognitive impairment across global societies.”   

Inflammation as a driver of social and planetary disruption  

These ideas shift our view of inflammation as a biological process restricted to an individual. Instead, the authors see it as a multiscale process linking molecular, cellular, and physiological interactions in each of us to altered decision-making and behavior in populations – and ultimately to large-scale societal and environmental impacts.  

“Stress-impaired judgment could explain the chaotic and counter-intuitive responses of large parts of the global population to stressful events such as climate change and the Covid-19 pandemic,” explained Vodovotz.  

“An inability to address these and other stressors may propagate a self-fulfilling sense of pervasive danger, causing further stress, inflammation, and impaired cognition in a runaway, positive feedback loop,” he added.  

The fact that current levels of global stress have not led to widespread societal disorder could indicate an equally strong stabilizing effect from “controllers” such as trust in laws, science, and multinational organizations like the United Nations.   

“However, societal norms and institutions are increasingly being questioned, at times rightly so as relics of a foregone era,” said Prof Paul Verschure of Radboud University, the Netherlands, and a co-author of the article. “The challenge today is how we can ward off a new adversarial era of instability due to global stress caused by a multi-scale combination of geopolitical fragmentation, conflicts, and ecological collapse amplified by existential angst, cognitive overload, and runaway disinformation.”    

Reducing social media exposure as part of the solution  

The authors developed a mathematical model to test their ideas and explore ways to reduce stress and build resilience.  

“Preliminary results highlight the need for interventions at multiple levels and scales,” commented co-author Prof Julia Arciero of Indiana University, USA.  

“While anti-inflammatory drugs are sometimes used to treat medical conditions associated with inflammation, we do not believe these are the whole answer for individuals,” said Dr David Katz, co-author and a specialist in preventive and lifestyle medicine based in the US. “Lifestyle changes such as healthy nutrition, exercise, and reducing exposure to stressful online content could also be important.”  

“The dawning new era of precision and personalized therapeutics could also offer enormous potential,” he added.  

At the societal level, the authors suggest creating calm public spaces and providing education on the norms and institutions that keep our societies stable and functioning.  

“While our ‘inflammation map’ hypothesis and corresponding mathematical model are a start, a coordinated and interdisciplinary research effort is needed to define interventions that would improve the lives of individuals and the resilience of communities to stress. We hope our article stimulates scientists around the world to take up this challenge,” Vodovotz concluded.  

The article is part of the Frontiers in Science multimedia article hub ‘A multiscale map of inflammatory stress’. The hub features a video, an explainer, a version of the article written for kids, and an editorial, viewpoints, and policy outlook from other eminent experts: Prof David Almeida (Penn State University, USA), Prof Pietro Ghezzi (University of Urbino Carlo Bo, Italy), and Dr Ioannis P Androulakis (Rutgers, The State University of New Jersey, USA). 


Read More

Continue Reading

International

Acadia’s Nuplazid fails PhIII study due to higher-than-expected placebo effect

After years of trying to expand the market territory for Nuplazid, Acadia Pharmaceuticals might have hit a dead end, with a Phase III fail in schizophrenia…

Published

on

After years of trying to expand the market territory for Nuplazid, Acadia Pharmaceuticals might have hit a dead end, with a Phase III fail in schizophrenia due to the placebo arm performing better than expected.

Steve Davis

“We will continue to analyze these data with our scientific advisors, but we do not intend to conduct any further clinical trials with pimavanserin,” CEO Steve Davis said in a Monday press release. Acadia’s stock $ACAD dropped by 17.41% before the market opened Tuesday.

Pimavanserin, a serotonin inverse agonist and also a 5-HT2A receptor antagonist, is already in the market with the brand name Nuplazid for Parkinson’s disease psychosis. Efforts to expand into other indications such as Alzheimer’s-related psychosis and major depression have been unsuccessful, and previous trials in schizophrenia have yielded mixed data at best. Its February presentation does not list other pimavanserin studies in progress.

The Phase III ADVANCE-2 trial investigated 34 mg pimavanserin versus placebo in 454 patients who have negative symptoms of schizophrenia. The study used the negative symptom assessment-16 (NSA-16) total score as a primary endpoint and followed participants up to week 26. Study participants have control of positive symptoms due to antipsychotic therapies.

The company said that the change from baseline in this measure for the treatment arm was similar between the Phase II ADVANCE-1 study and ADVANCE-2 at -11.6 and -11.8, respectively. However, the placebo was higher in ADVANCE-2 at -11.1, when this was -8.5 in ADVANCE-1. The p-value in ADVANCE-2 was 0.4825.

In July last year, another Phase III schizophrenia trial — by Sumitomo and Otsuka — also reported negative results due to what the company noted as Covid-19 induced placebo effect.

According to Mizuho Securities analysts, ADVANCE-2 data were disappointing considering the company applied what it learned from ADVANCE-1, such as recruiting patients outside the US to alleviate a high placebo effect. The Phase III recruited participants in Argentina and Europe.

Analysts at Cowen added that the placebo effect has been a “notorious headwind” in US-based trials, which appears to “now extend” to ex-US studies. But they also noted ADVANCE-1 reported a “modest effect” from the drug anyway.

Nonetheless, pimavanserin’s safety profile in the late-stage study “was consistent with previous clinical trials,” with the drug having an adverse event rate of 30.4% versus 40.3% with placebo, the company said. Back in 2018, even with the FDA approval for Parkinson’s psychosis, there was an intense spotlight on Nuplazid’s safety profile.

Acadia previously aimed to get Nuplazid approved for Alzheimer’s-related psychosis but had many hurdles. The drug faced an adcomm in June 2022 that voted 9-3 noting that the drug is unlikely to be effective in this setting, culminating in a CRL a few months later.

As for the company’s next R&D milestones, Mizuho analysts said it won’t be anytime soon: There is the Phase III study for ACP-101 in Prader-Willi syndrome with data expected late next year and a Phase II trial for ACP-204 in Alzheimer’s disease psychosis with results anticipated in 2026.

Acadia collected $549.2 million in full-year 2023 revenues for Nuplazid, with $143.9 million in the fourth quarter.

Read More

Continue Reading

Uncategorized

Digital Currency And Gold As Speculative Warnings

Over the last few years, digital currencies and gold have become decent barometers of speculative investor appetite. Such isn’t surprising given the evolution…

Published

on

Over the last few years, digital currencies and gold have become decent barometers of speculative investor appetite. Such isn’t surprising given the evolution of the market into a “casino” following the pandemic, where retail traders have increased their speculative appetites.

“Such is unsurprising, given that retail investors often fall victim to the psychological behavior of the “fear of missing out.” The chart below shows the “dumb money index” versus the S&P 500. Once again, retail investors are very long equities relative to the institutional players ascribed to being the “smart money.””

“The difference between “smart” and “dumb money” investors shows that, more often than not, the “dumb money” invests near market tops and sells near market bottoms.”

Net Smart Dumb Money vs Market

That enthusiasm has increased sharply since last November as stocks surged in hopes that the Federal Reserve would cut interest rates. As noted by Sentiment Trader:

“Over the past 18 weeks, the straight-up rally has moved us to an interesting juncture in the Sentiment Cycle. For the past few weeks, the S&P 500 has demonstrated a high positive correlation to the ‘Enthusiasm’ part of the cycle and a highly negative correlation to the ‘Panic’ phase.”

Investor Enthusiasm

That frenzy to chase the markets, driven by the psychological bias of the “fear of missing out,” has permeated the entirety of the market. As noted in This Is Nuts:”

“Since then, the entire market has surged higher following last week’s earnings report from Nvidia (NVDA). The reason I say “this is nuts” is the assumption that all companies were going to grow earnings and revenue at Nvidia’s rate. There is little doubt about Nvidia’s earnings and revenue growth rates. However, to maintain that growth pace indefinitely, particularly at 32x price-to-sales, means others like AMD and Intel must lose market share.”

Nvidia Price To Sales

Of course, it is not just a speculative frenzy in the markets for stocks, specifically anything related to “artificial intelligence,” but that exuberance has spilled over into gold and cryptocurrencies.

Birds Of A Feather

There are a couple of ways to measure exuberance in the assets. While sentiment measures examine the broad market, technical indicators can reflect exuberance on individual asset levels. However, before we get to our charts, we need a brief explanation of statistics, specifically, standard deviation.

As I discussed in “Revisiting Bob Farrell’s 10 Investing Rules”:

“Like a rubber band that has been stretched too far – it must be relaxed in order to be stretched again. This is exactly the same for stock prices that are anchored to their moving averages. Trends that get overextended in one direction, or another, always return to their long-term average. Even during a strong uptrend or strong downtrend, prices often move back (revert) to a long-term moving average.”

The idea of “stretching the rubber band” can be measured in several ways, but I will limit our discussion this week to Standard Deviation and measuring deviation with “Bollinger Bands.”

“Standard Deviation” is defined as:

“A measure of the dispersion of a set of data from its mean. The more spread apart the data, the higher the deviation. Standard deviation is calculated as the square root of the variance.”

In plain English, this means that the further away from the average that an event occurs, the more unlikely it becomes. As shown below, out of 1000 occurrences, only three will fall outside the area of 3 standard deviations. 95.4% of the time, events will occur within two standard deviations.

Standard Deviation Chart

A second measure of “exuberance” is “relative strength.”

“In technical analysis, the relative strength index (RSI) is a momentum indicator that measures the magnitude of recent price changes to evaluate overbought or oversold conditions in the price of a stock or other asset. The RSI is displayed as an oscillator (a line graph that moves between two extremes) and can read from 0 to 100.

Traditional interpretation and usage of the RSI are that values of 70 or above indicate that a security is becoming overbought or overvalued and may be primed for a trend reversal or corrective pullback in price. An RSI reading of 30 or below indicates an oversold or undervalued condition.” – Investopedia

With those two measures, let’s look at Nvidia (NVDA), the poster child of speculative momentum trading in the markets. Nvidia trades more than 3 standard deviations above its moving average, and its RSI is 81. The last time this occurred was in July of 2023 when Nvidia consolidated and corrected prices through November.

NVDA chart vs Bollinger Bands

Interestingly, gold also trades well into 3 standard deviation territory with an RSI reading of 75. Given that gold is supposed to be a “safe haven” or “risk off” asset, it is instead getting swept up in the current market exuberance.

Gold vs Bollinger Bands

The same is seen with digital currencies. Given the recent approval of spot, Bitcoin exchange-traded funds (ETFs), the panic bid to buy Bitcoin has pushed the price well into 3 standard deviation territory with an RSI of 73.

Bitcoin vs Bollinger Bands

In other words, the stock market frenzy to “buy anything that is going up” has spread from just a handful of stocks related to artificial intelligence to gold and digital currencies.

It’s All Relative

We can see the correlation between stock market exuberance and gold and digital currency, which has risen since 2015 but accelerated following the post-pandemic, stimulus-fueled market frenzy. Since the market, gold and cryptocurrencies, or Bitcoin for our purposes, have disparate prices, we have rebased the performance to 100 in 2015.

Gold was supposed to be an inflation hedge. Yet, in 2022, gold prices fell as the market declined and inflation surged to 9%. However, as inflation has fallen and the stock market surged, so has gold. Notably, since 2015, gold and the market have moved in a more correlated pattern, which has reduced the hedging effect of gold in portfolios. In other words, during the subsequent market decline, gold will likely track stocks lower, failing to provide its “wealth preservation” status for investors.

SP500 vs Gold

The same goes for cryptocurrencies. Bitcoin is substantially more volatile than gold and tends to ebb and flow with the overall market. As sentiment surges in the S&P 500, Bitcoin and other cryptocurrencies follow suit as speculative appetites increase. Unfortunately, for individuals once again piling into Bitcoin to chase rising prices, if, or when, the market corrects, the decline in cryptocurrencies will likely substantially outpace the decline in market-based equities. This is particularly the case as Wall Street can now short the spot-Bitcoin ETFs, creating additional selling pressure on Bitcoin.

SP500 vs Bitcoin

Just for added measure, here is Bitcoin versus gold.

Gold vs Bitcoin

Not A Recommendation

There are many narratives surrounding the markets, digital currency, and gold. However, in today’s market, more than in previous years, all assets are getting swept up into the investor-feeding frenzy.

Sure, this time could be different. I am only making an observation and not an investment recommendation.

However, from a portfolio management perspective, it will likely pay to remain attentive to the correlated risk between asset classes. If some event causes a reversal in bullish exuberance, cash and bonds may be the only place to hide.

The post Digital Currency And Gold As Speculative Warnings appeared first on RIA.

Read More

Continue Reading

Trending